Winton Group’s Climb Bio CLYM Stock Holding History

Winton Group’s Portfolio CLYM Stock Details CLYM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-27,551	Closed	-$140K	–	825
2024 Q3	$140K	Buy	+27,551	New	+$195K	0.01%	585

Other funds holding CLYM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Winton Group's CLYM Position: Q4 2024 in Review

Winton Group sold out of Climb Bio (CLYM) in Q4 2024, closing a stake of 27,551 shares — an estimated $140K sold.

Winton Group first reported a position in CLYM in Q3 2024 and held it in 1 quarter. The position peaked at $140K in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q4 2024.

Winton Group reported no remaining Climb Bio position as of Q4 2024 after selling out during the quarter.
Winton Group sold 27,551 Climb Bio shares in Q4 2024, an estimated $140K.
Winton Group first reported a position in Climb Bio in Q3 2024 and held it in 1 quarter.
Winton Group's Climb Bio position peaked at $140K in Q3 2024.
80 funds tracked by Wall St. Rank held Climb Bio as of Q4 2024.

Based on Winton Group's 13F filing for Q4 2024, filed 12 Feb 2025.